# A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

> **NCT06108544** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 1108 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** TAK-279
- **DRUG:** Placebo
- **DRUG:** Apremilast

## Key facts

- **NCT ID:** NCT06108544
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-06
- **Primary completion:** 2024-12-06
- **Final completion:** 2025-11-07
- **Target enrollment:** 1108 (ACTUAL)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06108544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06108544, "A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06108544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*